Article · Volume 4, Issue 3 · pp. 224–224
A new drug belonging to a novel class of drugs for type 2 diabetes
Sivagnanam G1
- 1Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.
Abstract
The FDA approval of canagliflozin (Invokana) was based on data involving over 10,285 type 2 diabetes patients, which showed improvement in hemoglobin A1c and fasting plasma glucose levels. Canagliflozin has been tested as monotherapy as well as in combination with metformin, sulphonylurea, pioglitazone, and insulin
Keywords: News and Views
The full text of this article is available as a PDF. Open the PDF.